Malaysia

Population 2017  32 million

<table>
<thead>
<tr>
<th>Estimates of TB burden*, 2017</th>
<th>Number (thousands)</th>
<th>Rate (per 100 000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mortality (excludes HIV+TB)</td>
<td>1.3 (1.1–1.4)</td>
<td>4 (3.5–4.5)</td>
</tr>
<tr>
<td>Mortality (HIV+TB only)</td>
<td>0.3 (0.22–0.38)</td>
<td>0.93 (0.69–1.2)</td>
</tr>
<tr>
<td>Incidence (includes HIV+TB)</td>
<td>29 (25–34)</td>
<td>93 (79–107)</td>
</tr>
<tr>
<td>Incidence (HIV+TB only)</td>
<td>1.8 (1.5–2.1)</td>
<td>57 (4.8–6.6)</td>
</tr>
<tr>
<td>Incidence (MDR/RR-TB)**</td>
<td>0.49 (0.37–0.63)</td>
<td>1.5 (1.2–2)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Estimated TB incidence by age and sex (thousands)*, 2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>0-14 years</td>
</tr>
<tr>
<td>Females</td>
</tr>
<tr>
<td>Males</td>
</tr>
<tr>
<td>Total</td>
</tr>
</tbody>
</table>

TB case notifications, 2017

- Total cases notified: 26 168
- Total new and relapse: 25 464

- % tested with rapid diagnostics at time of diagnosis: 87%
- % with known HIV status: 85%
- % bacteriologically confirmed among pulmonary: 74%

Universal health coverage and social protection

- TB treatment coverage (notified/estimated incidence), 2017: 87% (75–100)
- TB patients facing catastrophic total costs
- TB case fatality ratio (estimated mortality/estimated incidence), 2017: 0.05 (0.04–0.06)
- TB/HIV care in new and relapse TB patients, 2017
  - Number (%)
  - Patients with known HIV-status who are HIV-positive: 1 356 6%
  - on antiretroviral therapy: 949 70%

Drug-resistant TB care, 2017

- Estimated MDR/RR-TB cases among notified pulmonary TB cases: 370 (290–460)
- Estimated % of TB cases with MDR/RR-TB: 1.5% (1.2–1.9) 3.1% (1.3–5.9)
- % notified tested for rifampicin resistance: 47% 46% 15 432
- MDR/RR-TB cases tested for resistance to second-line drugs: 65
- Laboratory-confirmed cases: MDR/RR-TB: 352, XDR-TB: 1
- Patients started on treatment ****: MDR/RR-TB: 97, XDR-TB: 0

Treatment success rate and cohort size

- New and relapse cases registered in 2016: 80% 25 005
- Previously treated cases, excluding relapse, registered in 2016: 50% 736
- HIV-positive TB cases registered in 2016: 56% 1 406
- MDR/RR-TB cases started on second-line treatment in 2015: 41% 85
- XDR-TB cases started on second-line treatment in 2015: 0

TB preventive treatment, 2017

- % of HIV-positive people (newly enrolled in care) on preventive treatment: 79%
- % of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment: 100% (87–100)

TB financing, 2018

- National TB budget (US$ millions): 16
- Funding source: 100% domestic, international, 0% unfunded

* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2017 and patients who were not laboratory-confirmed

Data: www.who.int/tb/data